» Authors » Antonia Lepida

Antonia Lepida

Explore the profile of Antonia Lepida including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 74
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Otero Sanchez L, Zhan C, Gomes Da Silveira Cauduro C, Crenier L, Njimi H, Englebert G, et al.
JHEP Rep . 2023 Jul; 5(8):100791. PMID: 37456681
Background & Aims: Diabetes mellitus is a major risk factor for fatty liver disease development and progression. A novel machine learning method identified five clusters of patients with diabetes, with...
2.
Weichselbaum L, Lepida A, Marot A, Trepo E, Moreno C, Deltenre P
United European Gastroenterol J . 2022 Oct; 10(8):874-887. PMID: 36217553
Background: Transjugular intrahepatic portosystemic shunt (TIPS) may be used as a salvage treatment in patients with cirrhosis and refractory variceal bleeding. Aim: To synthesize the available evidence on the efficacy...
3.
Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, et al.
Diagnostics (Basel) . 2022 Feb; 12(2). PMID: 35204627
Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) significantly improve the outcomes of patients with advanced clear cell renal cell carcinoma (ccRCC); however, high-grade toxicities can occur, particularly during...
4.
Engelman D, Moreau M, Lepida A, Zaouak Y, Paesmans M, Awada A
ESMO Open . 2020 Jun; 5(3):e000695. PMID: 32487541
Purpose: Pseudocirrhosis is a radiological term used to describe rapid changes in the contour of liver invaded by metastases and treated with chemotherapy. Our primary objectives were to analyse the...
5.
Weichselbaum L, Azouz A, Smolen K, Das J, Splittgerber M, Lepida A, et al.
J Hepatol . 2020 Mar; 73(2):303-314. PMID: 32145259
Background & Aims: Severe forms of alcohol-related liver disease are associated with increased susceptibility to infections which are associated with poor prognosis. The cellular and molecular mechanisms responsible for this...
6.
Lepida A, Marot A, Trepo E, Degre D, Moreno C, Deltenre P
Aliment Pharmacol Ther . 2019 Oct; 50(9):978-987. PMID: 31583729
Background: Few effective treatments are available for patients with cirrhosis and refractory ascites. New treatment modalities are needed for these patients. Aim: To synthesise the available evidence on the efficacy...
7.
Degre D, Serste T, Lasser L, Delwaide J, Starkel P, Laleman W, et al.
PLoS One . 2017 Jan; 12(1):e0170933. PMID: 28125694
Introduction: Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in...
8.
Degre D, Gustot T, Gerkens A, Boon N, Schreiber J, Lepida A, et al.
Eur J Gastroenterol Hepatol . 2016 Mar; 28(7):792-6. PMID: 26982337
Background And Aim: Insulin resistance plays an important role in chronic liver disease, where it has been associated with the progression of fibrosis and correlated with portal hypertension in cirrhotic...
9.
Lepida A, Colombo M, Fernandez I, Abdurakhmanov D, Ferreira P, Strasser S, et al.
PLoS One . 2015 Sep; 10(9):e0138503. PMID: 26398503
Background: Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and cirrhosis in chronic hepatitis C patients. We evaluated...
10.
Serste T, Njimi H, Degre D, Deltenre P, Schreiber J, Lepida A, et al.
Liver Int . 2015 Jan; 35(8):1974-82. PMID: 25611961
Background & Aims: The beneficial effect of nonselective beta-blockers (NSBB) has recently been questioned in patients with end-stage cirrhosis. We analysed the impact of NSBB on outcomes in severe alcoholic...